Perception of another person's maximum reach-with-jump height from walking kinematics.

Humans can perceive affordances (possibilities for action) for themselves and others, including the maximum overhead height reachable by jumping (reach-with-jump height, RWJ). While observers can accurately perceive maximum RWJ for another person without previously seeing the person jump, estimates improve after viewing the person walk, suggesting there is structure in walking kinematics that is informative about the ability to produce vertical force for jumping. We used principal component analysis (PCA) to identify patterns in human walking kinematics that specify another person's maximum RWJ ability, and to determine whether athletes are more sensitive than non-athletes to these patterns. Kinematic data during treadmill walking were collected and submitted to PCA to obtain loading values for the kinematic time series variables on the first principal component. Kinematic data were also used to create point-light (PL) displays, in which the movement kinematics of PL walkers were manipulated using the obtained PCA loading values to determine how changes in body-segment movements impacted perception of maximum RWJ height. While manipulating individual segmental loadings in the PL displays did not substantially affect RWJ estimates, PL displays created by replacing the PCA loadings of a high-jumper with those of a low-jumper, and vice versa, resulted in corresponding reversals of participants' RWJ estimates, suggesting that the global structure of walking kinematics carries information about another's maximum RWJ height. Athletes exhibited greater sensitivity than controls to the kinematic manipulations, indicating that they are better attuned to useful kinematic information as a result of their sport experience.

Parental perceptions of the benefits of neuropsychological assessment in a neurodevelopmental outpatient clinic.

The present study examines the utility and value ratings of neuropsychological evaluation by measuring patient (parent) perceptions, as well as determining whether testing led to diagnostic changes of specific recommendations. Sixty-four children ages 4-16 received a neuropsychological examination. A 5-point Likert questionnaire yielded an overall utility mean of 3.89 (SD =.82). The greatest utility mean rating, 4.4, was "understanding of strengths and weaknesses," and the lowest utility, 3.52, was "documenting treatment progress." Parents reported a mean utility of 4.5 for "money spent" and 4.7 for "time spent." Forty-eight percent received a new psychiatric diagnosis, 22% had a psychiatric diagnosis eliminated, and 51% had a psychiatric diagnosis confirmed. Forty-four percent received a new diagnosis of learning disability or other cognitive disorder.

Impact of Autism Navigator on Access to Services.

OBJECTIVE: To determine whether access to an Autism Patient Navigator (APN) for children diagnosed with autism spectrum disorder (ASD) at <48 months of age would be useful and lead to more appointments with needed services. METHOD: Participants included parents of 39 children diagnosed with ASD in a multidisciplinary clinic. After diagnosis, the patients were randomized to 4 groups: Medicaid early (n = 9) or late support (n = 9) and non-Medicaid early (n = 11) or late support (n = 10). Early access to the APN was at the family meeting and later at 3 months after diagnosis. Data included demographic information and completion by phone interview at 3 months postdiagnosis of a questionnaire on the usefulness of the assessment and parent's desire or ability to obtain recommended services. RESULTS: Demographically, the groups were not different. Children were most frequently male, white, non-Hispanic, and non-Medicaid with a mean age of 35 months. In comparison with the non-Medicaid groups, the Medicaid groups more often endorsed the 9 questions on the usefulness of the assessment as being "A Great Deal" useful (p = .022). Groups with early support were more successful in scheduling or completing appointments for recommended services overall including medical, educational, therapeutic, and parent resource appointments (p = .031). Barriers to services or resources were reported by 35.9%. CONCLUSION: Parents of young children with Medicaid with a recent diagnosis of ASD found the assessment "very useful" compared with non-Medicaid group. The groups with immediate access to an APN were more successful with scheduling and completing appointments.

Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder.

BACKGROUND: The use of antipsychotic medications to treat aggression in youths with autism spectrum disorders (ASD) is based on open-label trials and efficacy studies. There are no studies examining the combined effectiveness of antipsychotic medications and intensive behavioral intervention (IBI) to treat aggression in ASD. METHODS: Youths with ASD and aggressive behavior received IBI. Medication use remained stable during the study period and was coded into antipsychotic, mood-stabilizing, and nonstimulant attention-deficit/hyperactivity disorder (ADHD)/sleep medication classes. Analysis of covariance (ANCOVA) and survival analyses examined the effects of medication classes on the average number of aggressive behaviors and time to behavior plan success. RESULTS: Thirty-two youths (mean age = 11.16, standard deviation [SD] = 3.31, range = 4-16 years, 75% male) with ASD received aggression reduction plans. Of these, 25 youths were taking at least one psychiatric medication (antipsychotic n = 18, mood stabilizing n = 10, and nonstimulant ADHD/sleep n = 12). Aggression dropped substantially following implementation of IBI (p < 0.001; d = 1.70). Antipsychotic medication use predicted significantly fewer sessions to achieve behavior plan success (chi(2)(1) = 5.67, p = 0.017; d = 0.93). No other medication classes influenced aggressive behavior (largest chi(2)(1) = 0.16, p = 0.694). CONCLUSIONS: Behavioral treatment combined with antipsychotic medication was the most effective approach to reducing aggressive behaviors in youths with ASD. Mood-stabilizing and nonstimulant ADHD/sleep medications did not contribute to aggression reduction.